V. Pilipovic

Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non‐frequently exacerbating COPD patients: The FLASH randomized controlled trial

P. Frith, K. Kostikas, P. Olsson, 2018, Respirology.

Clinical Features and Outcome of Sickle Cell Disease in a Tertiary Center in Northern Lebanon: A Retrospective Cohort Study in a Local, Hospital-Associated Registry

A. Inati, H. Kanakamedala, V. Pilipovic, 2021, Hemoglobin.

A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study

H. Kuo, G. Juvelekian, F. Yunus, 2015, International journal of chronic obstructive pulmonary disease.

PF701 ASSESSMENT OF ELTROMBOPAG IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA UNDER ROUTINE CLINICAL PRACTICE IN THE MIDDLE EAST, TURKEY, ASIA, AND AUSTRALIA

R. Wong, I. Yavaşoğlu, P. Angchaisuksiri, 2019, HemaSphere.

a real-world evaluation of indacaterol and other bronchodilators in COPD: the InFlOW study

H. Kuo, G. Juvelekian, F. Yunus, 2015 .

a real-world evaluation of indacaterol and other bronchodilators in COPD: the InFlOW study

H. Kuo, G. Juvelekian, F. Yunus, 2015 .

Everolimus as first-line or after cytokine therapy in patients with metastatic recurrent and/or unresectable renal cell carcinoma (RCC) (EVERMORE).

Y. Nouira, H. Boussen, C. Pripatnanont, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.